SCHEMBL4650754

SCHEMBL4650754

CCCCCCCCCCCCCCCC(=O)C1CC(=O)N(O)C1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 6/20 0.46
LMNA P02545 5/20 0.40
ALDH1A1 P00352 4/20 0.40
MAPT P10636 4/20 0.40
HPGD P15428 4/20 0.40
HSD17B10 Q99714 3/20 0.40
HTT P42858 2/20 0.40
TSHR P16473 1/20 0.40
HSP90AA1 P07900 4/20 0.39
NAAA Q02083 2/20 0.39
FAAH O00519 1/20 0.39
CES2 O00748 3/20 0.38
CES1 P23141 3/20 0.38
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
ALOX15 P16050 1/20 0.38
ALOX12 P18054 1/20 0.38
KMT2A Q03164 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27983508 1.00 PRKCA (0.46) PRKCALMNAALDH1A1MAPTHPGD
SCHEMBL1935917 1.00 PRKCA (0.46) PRKCALMNAALDH1A1MAPTHPGD
SCHEMBL27309683 0.98 PRKCA (0.43) PRKCALMNAALDH1A1MAPTHPGD
Ammonia Solution, Strong SCHEMBL28872308 0.97 PRKCA (0.42) PRKCALMNAALDH1A1MAPTHPGD
SCHEMBL8192444 0.87 LMNA (0.39) PRKCALMNAALDH1A1MAPTHPGD
SCHEMBL1133829 0.84 ALDH1A1 (0.40) PRKCALMNAALDH1A1MAPTHPGD
SCHEMBL5061804 0.79 BRD4 (0.33)
SCHEMBL129229 0.78 PTGS1 (0.53) LMNAALDH1A1MAPTHPGDHTT
SCHEMBL27689659 0.78 ALDH1A1 (0.38) PRKCALMNAALDH1A1MAPTHPGD
SCHEMBL7824143 0.78 PRKCA (0.51) PRKCALMNAALDH1A1HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1202748-B1 POLYCATION-BASED BIOCONJUGATES SZEGOE PETER (HU) 2008-09-17 EP disclosed
US-7090846-B2 Method for preparing polycation based bioconjugates suitable for transporting different kinds of active substances within the body REFUAH RESEARCH, INC. (US) 2006-08-15 US disclosed
US-20040220083-A1 Method for preparing polycation based bioconjugates suitable for transporting different kinds of active substances within the body REFUAH RESEARCH, INC. 2004-11-04 US disclosed
US-6727347-B1 USED TO INHIBIT MALIGNANT CELL PROLIFERATION, POSSESS ANTIMICROBIAL EFFECT, OR GENE TRANSPORT CONFIGURATION REFUAH RESEARCH, INC. 2004-04-27 US disclosed
EP-1202748-A2 POLYCATION-BASED BIOCONJUGATES Szeg&Odblac, Péter (HU) 2002-05-08 EP disclosed
WO-2001000242-A2 POLYCATION-BASED BIOCONJUGATES SZEGOE PETER (HU) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220083-A1 Method for preparing polycation based bioconjugates suitable for transporting different kinds of active substances within the body ABCB11, SLC47A1, SLC67A1 PRKCA 3972/4885LMNA 3340/4885ALDH1A1 1561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.